FDA Drug Safety Office Needs Better System To Track Recommendations

An internal review of FDA's Office of Drug Safety has identified follow-up on recommendations as a central area for improvement, Office of Pharmacoepidemiology & Statistical Science Director Paul Seligman told a July 20 meeting of the Institute of Medicine Committee on the Assessment of the U.S. Drug Safety System